MDGL Secures Exclusive Global Right for MASH Treatment From PFE

Key Takeaways Madrigal has licensed global rights to ervogastat to build combination therapies for MASH.Ervogastat cut liver fat in a phase II study, with up to 72% patients hitting a 30% reduction on MRI-PDFF.MDGL eyes drug-to-drug interaction work with Rezdiffra, and FDA talks ahead of a phase II combination study.Madrigal Pharmaceuticals (MDGL) has acquired exclusive global rights to ervogastat from Pfizer (PFE) , strengthening its pipeline of innovative and combination therapies for metabolic dysfunctio ...